JPH06508610A - 医薬組成物 - Google Patents
医薬組成物Info
- Publication number
- JPH06508610A JPH06508610A JP4510527A JP51052792A JPH06508610A JP H06508610 A JPH06508610 A JP H06508610A JP 4510527 A JP4510527 A JP 4510527A JP 51052792 A JP51052792 A JP 51052792A JP H06508610 A JPH06508610 A JP H06508610A
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- compound
- sialic acid
- active ingredient
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims (25)
- 1.活性成分を含む医薬組成物の製造方法における多糖化合物の使用であって、 多糖化合物が多糖1分子当たり5つ以上のシアル酸単位を含んでおり、該多糖化 合物を、患者の血液循環における前記活性成分の有効時間を延ばし、前記活性成 分の免疫原性を低下させ、及び/又はin vivoでの前記活性成分の安定性 を増加させるのに十分な量で含ませる前記使用。
- 2.活性成分と、患者の血液循環における前記活性成分の有効時間を延ばし、前 記活性成分の免疫原性を低下させ、及び/又はin vivoでの前記活性成分 の安定性を増加させるのに十分な量の多糖化合物とを組み合わせて含む医薬組成 物であって、前記多糖化合物が多糖1分子当たり5つ以上のシアル酸単位を含ん でいる医薬組成物。
- 3.患者の血液循環における医薬的活性成分の有効時間を延ばし、前記活性成分 の免疫原性を低下させ、及び/又はin vivoでの前記活性成分の安定性を 増加させるための、多糖1分子当たり5つ以上のシアル酸単位を含む多糖化合物 の使用。
- 4.活性成分と多糖とが、例えば共有結合又は疎水性結合によって互いに直接結 合している、請求項1もしくは3に記載の使用、又は請求項2に記載の組成物。
- 5.活性成分と多糖とが、例えば高分子薬物給送システム又は粒状薬物給送シス テムのような薬物給送システムを介して互いに結合している、請求項1もしくは 3に記載の使用、又は請求項2に記載の組成物。
- 6.多糖化合物が、例えば疎水性結合又はイオン結合のような共有的又は非共有 的結合によって薬物給送システムに結合する請求項5に記載の使用又は組成物。
- 7.薬物給送システムが、表面に多糖化合物の多糖成分を含んでいるリボソーム からなる請求項5又は6に記載の使用又は組成物。
- 8.薬物給送システムが高分子DDSであり、多糖化合物に共有的に結合するペ プチド又はタンパク質からなる請求項5又は6に記載の使用又は組成物。
- 9.多糖化合物が、任意の初期の急速排除ステップ後の血液循環における該化合 物の半減期が10時間以上、好ましくは20時間以上、より好ましくは30時間 以上であるような化合物である請求項1から8のいずれか一項に記載の使用又は 組成物。
- 10.多糖化合物が細菌多糖もしくはその誘導体、又はこの種の多糖もしくは誘 導体の合成類似体である請求項1から9のいずれか一項に記載の使用又は組成物 。
- 11.多糖が多糖成分中に、1分子当たり20以上、好ましくは50以上、より 好ましくは100以上、例えば約200のシアル酸残基を有している請求項1か ら10のいずれか一項に記載の組成物又は使用。
- 12.多糖が末端ガラクトース、フコース及びマンノース単位を実質的に含んで いない請求項1から11のいずれか一項に記載の組成物又は使用。
- 13.多糖化合物が、N.meningitidis、大腸菌K1、morax e11a nonliquifaciens及びPasteurella ae roginosisのグループB多糖、並びにN.meningitidisの グループC、大腸菌K92多糖及び大腸菌K1から誘導したコロミン酸から選択 したものである請求項12に記載の組成物又は使用。
- 14.多糖化合物が、脂肪酸鎖を除去するためにアルカリ加水分解にかけた糖脂 質の誘導体である請求項13に記載の組成物又は使用。
- 15.活性成分が、好ましくは共有的に多糖化合物に結合しているペプチド又は タンパク質からなる請求項1から14のいずれか一項に記載の組成物又は使用。
- 16.1分子当たり5つ以上のシアル酸単位を有する多糖部分が外面に結合して いるリボソーム。
- 17.多糖部分が、リボソームの脂質層中に導入された疎水部分も含む多糖化合 物の一部分をなしている請求項16に記載のリボソーム。
- 18.多糖化合物が天然の糖脂質であるか、又は天然の脂質基を含む前記糖脂質 の誘導体である請求項17に記載のリボソーム。
- 19.多糖化合物が、疎水部分を共有的に結合した天然多糖の誘導体であり、前 記疎水部分が、好ましくは多糖部分のシアル酸単位に共有結合しており、より好 ましくは1−位置又は窒素原子を介して共有結合している請求項17に記載のリ ボソーム。
- 20.療法又は診断方法で使用するための医薬の製造における請求項16から1 9のいずれか一項に記載のリボソームの使用。
- 21.リボソーム形成脂質の混合物と、1分子当たり5つ以上のシアル酸単位を 含む多糖成分を有すると共に疎水部分を有する多糖化合物とからリボソームを製 造する方法。
- 22.多糖化合物が天然の糖脂質であるか、又は天然の脂質基を含む前記糖脂質 の誘導体である請求項21に記載の方法。
- 23.多糖化合物が、疎水部分を共有的に結合した天然多糖の誘導体であり、前 記疎水部分が、好ましくは多糖部分のシアル酸単位に共有結合しており、より好 ましくは1−位置又は窒素原子を介して共有結合している請求項21に記載の方 法。
- 24.多糖化合物が、シアル酸残基の1−位置で共有結合により結合した疎水基 を含んでいる請求項23に記載の方法。
- 25.疎水基と多糖部分とを含む多糖化合物であって、多糖部分が1分子当たり 5つ以上のシアル酸単位を有し、疎水基が1−位置又は窒素原子を介して多糖部 分のシアル酸残基に共有結合している多糖化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919112212A GB9112212D0 (en) | 1991-06-06 | 1991-06-06 | Pharmaceutical compositions |
GB9112212.7 | 1991-06-06 | ||
PCT/GB1992/001022 WO1992022331A1 (en) | 1991-06-06 | 1992-06-08 | Pharmaceutical compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005042054A Division JP4332507B2 (ja) | 1991-06-06 | 2005-02-18 | 医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06508610A true JPH06508610A (ja) | 1994-09-29 |
JP3671054B2 JP3671054B2 (ja) | 2005-07-13 |
Family
ID=10696221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51052792A Expired - Fee Related JP3671054B2 (ja) | 1991-06-06 | 1992-06-08 | 医薬組成物 |
JP2005042054A Expired - Lifetime JP4332507B2 (ja) | 1991-06-06 | 2005-02-18 | 医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005042054A Expired - Lifetime JP4332507B2 (ja) | 1991-06-06 | 2005-02-18 | 医薬組成物 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0587639B1 (ja) |
JP (2) | JP3671054B2 (ja) |
KR (1) | KR100354944B1 (ja) |
AT (1) | ATE204179T1 (ja) |
CA (1) | CA2109952C (ja) |
DE (1) | DE69232006T2 (ja) |
DK (1) | DK0587639T3 (ja) |
ES (1) | ES2161214T3 (ja) |
GB (1) | GB9112212D0 (ja) |
WO (1) | WO1992022331A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509900A (ja) | 2000-09-22 | 2004-04-02 | オーファン メディカル,インコーポレイティド | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
JP2007501888A (ja) * | 2003-08-12 | 2007-02-01 | リポクセン テクノロジーズ リミテッド | ポリシアル酸誘導体 |
JP2007501889A (ja) * | 2003-08-12 | 2007-02-01 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のためのシアル酸誘導体 |
JP2008510025A (ja) * | 2004-08-12 | 2008-04-03 | リポクセン テクノロジーズ リミテッド | シアル酸誘導体 |
JP2008531764A (ja) * | 2005-02-23 | 2008-08-14 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のための活性化シアル酸誘導体 |
JP2010512753A (ja) * | 2006-12-15 | 2010-04-30 | バクスター・インターナショナル・インコーポレイテッド | 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221386B1 (en) | 1996-03-08 | 2001-04-24 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents |
JP2003533537A (ja) | 2000-05-16 | 2003-11-11 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化 |
GB0129121D0 (en) * | 2001-12-05 | 2002-01-23 | Ic Vec Ltd | Compound |
AU2003233464A1 (en) * | 2002-03-29 | 2003-10-13 | Bristol-Myers Squibb Corporation | Lipid mediated screening of drug candidates for identification of active compounds |
US7875708B2 (en) * | 2004-08-12 | 2011-01-25 | Lipoxen Technologies Limited | Sialic acid derivatives |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
JP2009544681A (ja) | 2006-07-25 | 2009-12-17 | リポクセン テクノロジーズ リミテッド | エリスロポエチンの多糖誘導体 |
RU2473567C2 (ru) | 2007-02-28 | 2013-01-27 | Липоксен Текнолоджиз Лимитед | Способ снижения содержания эндотоксина в образце, содержащем полисиаловую кислоту и эндотоксин |
US9925209B2 (en) | 2008-03-19 | 2018-03-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same |
US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
EP2341941A4 (en) * | 2008-09-09 | 2014-12-10 | Univ Oklahoma | HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
WO2011012850A2 (en) * | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US9919002B2 (en) | 2013-10-21 | 2018-03-20 | North Carolina State University | Methods and constructs for compound delivery |
WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
WO2020099513A1 (en) | 2018-11-13 | 2020-05-22 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
DK17685D0 (da) * | 1985-01-14 | 1985-01-14 | Hans Goeran Magnusson | Glycosidderivater |
JP2666345B2 (ja) * | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
EP0349127B1 (en) * | 1988-07-01 | 1993-09-29 | The Biomembrane Institute | Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
JP2975632B2 (ja) * | 1990-03-30 | 1999-11-10 | 生化学工業株式会社 | グリコサミノグリカン修飾プロテイン |
-
1991
- 1991-06-06 GB GB919112212A patent/GB9112212D0/en active Pending
-
1992
- 1992-06-08 CA CA002109952A patent/CA2109952C/en not_active Expired - Fee Related
- 1992-06-08 DK DK92911095T patent/DK0587639T3/da active
- 1992-06-08 DE DE69232006T patent/DE69232006T2/de not_active Expired - Fee Related
- 1992-06-08 KR KR1019930703716A patent/KR100354944B1/ko not_active IP Right Cessation
- 1992-06-08 JP JP51052792A patent/JP3671054B2/ja not_active Expired - Fee Related
- 1992-06-08 AT AT92911095T patent/ATE204179T1/de not_active IP Right Cessation
- 1992-06-08 EP EP92911095A patent/EP0587639B1/en not_active Expired - Lifetime
- 1992-06-08 WO PCT/GB1992/001022 patent/WO1992022331A1/en active IP Right Grant
- 1992-06-08 ES ES92911095T patent/ES2161214T3/es not_active Expired - Lifetime
-
2005
- 2005-02-18 JP JP2005042054A patent/JP4332507B2/ja not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509900A (ja) | 2000-09-22 | 2004-04-02 | オーファン メディカル,インコーポレイティド | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
JP2007501888A (ja) * | 2003-08-12 | 2007-02-01 | リポクセン テクノロジーズ リミテッド | ポリシアル酸誘導体 |
JP2007501889A (ja) * | 2003-08-12 | 2007-02-01 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のためのシアル酸誘導体 |
US9452224B2 (en) | 2003-08-12 | 2016-09-27 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
US10406209B2 (en) | 2003-08-12 | 2019-09-10 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
JP2008510025A (ja) * | 2004-08-12 | 2008-04-03 | リポクセン テクノロジーズ リミテッド | シアル酸誘導体 |
JP2008531764A (ja) * | 2005-02-23 | 2008-08-14 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のための活性化シアル酸誘導体 |
JP2010512753A (ja) * | 2006-12-15 | 2010-04-30 | バクスター・インターナショナル・インコーポレイテッド | 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体 |
Also Published As
Publication number | Publication date |
---|---|
WO1992022331A1 (en) | 1992-12-23 |
CA2109952A1 (en) | 1992-12-23 |
GB9112212D0 (en) | 1991-07-24 |
KR100354944B1 (ko) | 2002-12-31 |
JP2005232172A (ja) | 2005-09-02 |
EP0587639A1 (en) | 1994-03-23 |
DE69232006D1 (de) | 2001-09-20 |
JP3671054B2 (ja) | 2005-07-13 |
EP0587639B1 (en) | 2001-08-16 |
DE69232006T2 (de) | 2002-04-25 |
ATE204179T1 (de) | 2001-09-15 |
DK0587639T3 (da) | 2001-12-10 |
ES2161214T3 (es) | 2001-12-01 |
JP4332507B2 (ja) | 2009-09-16 |
KR940701274A (ko) | 1994-05-28 |
CA2109952C (en) | 2003-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4332507B2 (ja) | 医薬組成物 | |
US5846951A (en) | Pharmaceutical compositions | |
Gregoriadis et al. | Polysialic acids: potential in drug delivery | |
Jain et al. | A review of glycosylated carriers for drug delivery | |
Minko | Drug targeting to the colon with lectins and neoglycoconjugates | |
US9526705B2 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy | |
CA1324080C (en) | Bioadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents | |
EP0662002B1 (en) | Alginate-bioactive agent conjugates | |
WO1988007365A1 (en) | Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents | |
US20060127310A1 (en) | Amplification of biotin-mediated targeting | |
JPH06500795A (ja) | 選択的トロピズムを有する粒状物ベクター、その製造法及びその製薬学的組成物 | |
JP2005535604A (ja) | 治療剤を含むポリマーナノ物品 | |
Pawar et al. | Polysaccharides as carriers of bioactive agents for medical applications | |
WO2008007932A1 (en) | Chitosan complex containing ph sensitive imidazole group and preparation method thereof | |
Yu et al. | Saccharide modified pharmaceutical nanocarriers for targeted drug and gene delivery | |
Turánek et al. | Modification of liposomal surface by polysaccharides: Preparation, characterization, and application for drug targeting | |
EP1011722B1 (en) | Substrates materials with bound cytokine-stimulating polysaccharides or bacterial nucleic acids | |
JPH07291853A (ja) | リポソームおよび薬物運搬体 | |
AU2003280761B2 (en) | Liposome | |
JPH09124512A (ja) | 肝臓ターゲティングのための水溶性の薬物−プルラン結合体製剤 | |
US6087342A (en) | Substrates having bound polysaccharides and bacterial nucleic acids | |
WO2005027873A2 (en) | Therapeutic aminoglycoside-containing hydrogel nanoparticles | |
McCormack et al. | Polysialic acids: in vivo properties and possible uses in drug delivery | |
JP2004284991A (ja) | N−アシルアミン化合物及びそれを用いた医療用組成物 | |
AU2002326564A1 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040119 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040304 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041124 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050418 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090422 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100422 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |